NIKKEI 225
38,285.14 +82.77 (+0.22%) HANG SENG
18,306.25 -7.61 (-0.04%) CRUDE OIL
79.27 +0.28 (+0.35%) GOLD FUTURES
2,318.10 -4.20 (-0.18%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,147.32 -959.72 (-1.92%)
Zentalis Pharmaceuticals, Inc. (ZNTL)
After hours:
| Previous close | 12.31 |
| Open | 12.34 |
| Bid | 12.41 x 200 |
| Ask | 12.47 x 200 |
| Day's range | 11.85 - 12.58 |
| 52-week range | 9.56 - 31.46 |
| Volume | |
| Avg. volume | 811,809 |
| Market cap | 882.694M |
| Beta (5Y monthly) | 1.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025 Final results from Phase 1 study of azenosertib in combination with gemcitabine in adult and pediatric patients with relapsed or refractory osteosarcoma to be presented at the 2024 ASCO Annual Meeting Projected cash runway into mid-2026 NEW YORK and SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasda
- GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on May 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 91,200 shares of the Company’s common stock to three newly
- GlobeNewswire
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Research supports azenosertib’s potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agentsNEW YORK and SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, will pr
